Given that autophagic deficits are complicators of tissue recovery in various neuromuscular disorders [64], including also muscular dystrophies due to COL6 [65] and DYSF [66] deficiencies, the expansion of the compound’s potential applicability could also reach beyond DMD treatment. This evidence concerns the gene DMD and muscular dystrophy.